Grace Therapeutics, Inc. (GRCE) Stock Score, Valuation & Financial Research

Grace Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GRCE

Grace Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.15. These figures are a research snapshot, not a buy or sell recommendation.

What Grace Therapeutics, Inc. does

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.

Company business and revenue

Research reporting period: 2026-03-31. A research update is not a new financial filing.

How the company makes money

Grace Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on developing proprietary drug candidates for rare and orphan diseases, with the goal of obtaining regulatory approval and subsequently commercializing these products or out-licensing them to partners.

Products and services

  • The company's primary product candidate is GTx-104, a novel injectable formulation of nimodipine for IV infusion intended for patients with aneurysmal subarachnoid hemorrhage (aSAH). It also maintains a pipeline of de-prioritized candidates, GTx-102 and GTx-101.

Brands and product families

  • GTx-104 — Lead clinical-stage drug candidate for aSAH. Source
  • GTx-102 — De-prioritized drug candidate. Source
  • GTx-101 — De-prioritized drug candidate. Source

Customer types

Hospitals.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on unnamed third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates. Source

Business strengths to evaluate

  • Intellectual property portfolio of more than 79 granted and pending patents Source

Business risks and research considerations

  • Receipt of a Complete Response Letter (CRL) from the FDA citing manufacturing and non-clinical deficiencies for GTx-104 Source
  • History of operating losses and uncertainty regarding future profitability Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GRCE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.15
Market capitalization:
34.99M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -21.45M
Free cash flow:
USD -8.87M
Cash:
USD 13.76M
Total debt:
USD 0.00
EPS:
USD -1.26

What stands out

  • Free cash flow is USD -8.87M, negative for the stored period.
  • The balance sheet shows USD 13.76M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 13.76M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GRCE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GRCE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is GRCE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for GRCE to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of GRCE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research GRCE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.